Payment overview · 2025
General Payments
$239.13
13 reported records · 8 companies
Healthcare provider profile · identity verified
Priyanka Varma
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SAGINAW, MI · NPI 1437883196
Verified facts
What the public records show
CMS Open Payments records show Priyanka Varma received $239.13 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.32 | 21.0% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $34.03 | 14.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.48 | 14.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.60 | 12.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.99 | 12.1% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $27.44 | 11.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.01 | 8.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.26 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.13 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.32 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $34.03 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| NUVARING Normalized: nuvaring |
Drug | Organon LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 85 |
| Lisinopril | Lisinopril | 278 | 52 |
| Metformin Hcl | Metformin Hcl | 257 | 47 |
| Omeprazole | Omeprazole | 242 | 45 |
| Losartan Potassium | Losartan Potassium | 212 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 26 |
| Baclofen | Baclofen | 144 | 51 |
| Montelukast Sodium | Montelukast Sodium | 143 | 24 |
| Potassium Chloride | Potassium Chloride | 137 | 25 |
| Gabapentin | Gabapentin | 134 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 54 |
| Famotidine | Famotidine | 114 | 21 |
| Trulicity | Dulaglutide | 106 | 22 |
| Jardiance | Empagliflozin | 85 | 16 |
| Ibuprofen | Ibuprofen | 83 | 23 |
| Furosemide | Furosemide | 69 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 14 |
| Farxiga | Dapagliflozin Propanediol | 66 | 13 |
| Allopurinol | Allopurinol | 63 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 19 |
| Eliquis | Apixaban | 59 | suppressed |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Glipizide | Glipizide | 57 | suppressed |
| Carvedilol | Carvedilol | 55 | suppressed |
| Lovastatin | Lovastatin | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 26 |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 14 |
| Tradjenta | Linagliptin | 43 | suppressed |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 14 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | 14 |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Portia | Levonorgestrel/Ethin.Estradiol | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $239.13 · 13 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ARISTADA, Cologuard Collection Kit, Kerendia, LYBALVI, NEXPLANON, NUVARING, REXULTI, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error